Affimed N.V. (0HL9.L)
USD 0.73
(1.12%)
USD 0.73
(1.12%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 114.93 Million EUR | -8.77% |
| 2022 | 130.88 Million EUR | 23.82% |
| 2021 | 105.7 Million EUR | 65.93% |
| 2020 | 63.7 Million EUR | 17.89% |
| 2019 | 54.03 Million EUR | 20.66% |
| 2018 | 44.78 Million EUR | 51.95% |
| 2017 | 29.47 Million EUR | -23.45% |
| 2016 | 38.5 Million EUR | 30.27% |
| 2015 | 29.55 Million EUR | 147.52% |
| 2014 | 11.94 Million EUR | -44.2% |
| 2013 | 21.4 Million EUR | 81.73% |
| 2012 | 11.77 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 19.86 Million EUR | -19.25% |
| 2024 Q2 | 15.76 Million EUR | -20.94% |
| 2023 Q1 | 36.38 Million EUR | -13.64% |
| 2023 FY | 119.41 Million EUR | -8.77% |
| 2023 Q2 | 31.54 Million EUR | -13.28% |
| 2023 Q4 | 24.6 Million EUR | -8.46% |
| 2023 Q3 | 26.87 Million EUR | -14.8% |
| 2022 FY | 130.88 Million EUR | 23.82% |
| 2022 Q3 | 34.09 Million EUR | 16.76% |
| 2022 Q2 | 29.2 Million EUR | 14.86% |
| 2022 Q1 | 25.42 Million EUR | -27.6% |
| 2022 Q4 | 42.12 Million EUR | 23.55% |
| 2021 FY | 105.7 Million EUR | 65.93% |
| 2021 Q1 | 15.74 Million EUR | -22.73% |
| 2021 Q2 | 27.23 Million EUR | 73.01% |
| 2021 Q3 | 27.46 Million EUR | 0.82% |
| 2021 Q4 | 35.11 Million EUR | 27.86% |
| 2020 Q4 | 20.37 Million EUR | 50.3% |
| 2020 FY | 63.7 Million EUR | 17.89% |
| 2020 Q3 | 13.55 Million EUR | -5.22% |
| 2020 Q2 | 14.3 Million EUR | -4.84% |
| 2020 Q1 | 15.03 Million EUR | -1.23% |
| 2019 Q3 | 14.51 Million EUR | 4.49% |
| 2019 Q2 | 13.88 Million EUR | 33.26% |
| 2019 FY | 54.03 Million EUR | 20.66% |
| 2019 Q1 | 10.42 Million EUR | -29.89% |
| 2019 Q4 | 15.21 Million EUR | 4.87% |
| 2018 Q4 | 14.86 Million EUR | 22.07% |
| 2018 Q1 | 8.43 Million EUR | 29.69% |
| 2018 FY | 44.78 Million EUR | 51.95% |
| 2018 Q3 | 12.17 Million EUR | 30.74% |
| 2018 Q2 | 9.31 Million EUR | 10.42% |
| 2017 Q2 | 7.4 Million EUR | -3.75% |
| 2017 Q3 | 7.88 Million EUR | 6.54% |
| 2017 Q4 | 6.5 Million EUR | -17.52% |
| 2017 Q1 | 7.68 Million EUR | -1.54% |
| 2017 FY | 29.47 Million EUR | -23.45% |
| 2016 Q2 | 10.59 Million EUR | 15.63% |
| 2016 FY | 38.5 Million EUR | 30.27% |
| 2016 Q1 | 9.16 Million EUR | 1.9% |
| 2016 Q4 | 7.8 Million EUR | -28.64% |
| 2016 Q3 | 10.94 Million EUR | 3.29% |
| 2015 Q3 | 8.51 Million EUR | 16.96% |
| 2015 Q4 | 8.99 Million EUR | 5.57% |
| 2015 Q2 | 7.28 Million EUR | 52.67% |
| 2015 Q1 | 4.76 Million EUR | -18.8% |
| 2015 FY | 29.55 Million EUR | 147.52% |
| 2014 FY | 11.94 Million EUR | -44.2% |
| 2014 Q1 | 10.08 Million EUR | 64.64% |
| 2014 Q2 | -6.44 Million EUR | -163.91% |
| 2014 Q3 | 2.43 Million EUR | 137.72% |
| 2014 Q4 | 5.87 Million EUR | 141.69% |
| 2013 Q1 | 2.81 Million EUR | 0.0% |
| 2013 Q4 | 6.12 Million EUR | -9.01% |
| 2013 Q2 | 5.72 Million EUR | 103.23% |
| 2013 FY | 21.4 Million EUR | 81.73% |
| 2013 Q3 | 6.72 Million EUR | 17.46% |
| 2012 FY | 11.77 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 98.879% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 71.885% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 58.31% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 19.322% |
| uniQure N.V. | 285.08 Million USD | 59.684% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 73.124% |
| bluebird bio, Inc. | 240.23 Million USD | 52.156% |
| Imunon, Inc. | 21.03 Million USD | -446.522% |
| Dynavax Technologies Corporation | 219.14 Million USD | 47.553% |
| Editas Medicine, Inc. | 247.3 Million USD | 53.524% |
| Illumina, Inc. | 3.81 Billion USD | 96.986% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 74.515% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 94.402% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 89.45% |
| Myriad Genetics, Inc. | 600.1 Million USD | 80.847% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 92.801% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 91.554% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 78.273% |
| Verastem, Inc. | 92.08 Million USD | -24.816% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.717% |
| Waters Corporation | 943.51 Million USD | 87.818% |
| Biogen Inc. | 5.2 Billion USD | 97.792% |
| Nektar Therapeutics | 190.9 Million USD | 39.794% |
| Perrigo Company plc | 1.52 Billion USD | 92.48% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -726.305% |
| Heron Therapeutics, Inc. | 120.65 Million USD | 4.742% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -157.317% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 93.418% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 49.739% |
| Evolus, Inc. | 189.75 Million USD | 39.431% |
| Adicet Bio, Inc. | 152.03 Million USD | 24.403% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -846.677% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 95.917% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 57.728% |
| FibroGen, Inc. | 398.11 Million USD | 71.13% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 94.566% |
| OPKO Health, Inc. | 574.68 Million USD | 80.0% |
| Homology Medicines, Inc. | 9.87 Million USD | -1063.909% |
| Geron Corporation | 70.44 Million USD | -63.166% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 93.615% |
| Exelixis, Inc. | 1.58 Billion USD | 92.757% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -13.993% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -106.141% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 79.162% |
| Zoetis Inc. | 2.76 Billion USD | 95.843% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 75.872% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -136.972% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 97.593% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -193.556% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 85.257% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 68.819% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 61.601% |
| Blueprint Medicines Corporation | 722.86 Million USD | 84.1% |
| Insmed Incorporated | 949.26 Million USD | 87.892% |
| TG Therapeutics, Inc. | 198.47 Million USD | 42.09% |
| Incyte Corporation | 1.19 Billion USD | 90.346% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 88.991% |